UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 255

Sortiert nach

Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis

Antimicrobial agents and chemotherapy, 2022-02, Vol.66 (2), p.e0160821

2022

Volltextzugriff (PDF)

Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis

Antimicrobial agents and chemotherapy, 2021-06, Vol.65 (7), p.e0268720-e0268720

2021

Volltextzugriff (PDF)

Constructing a representative in‐silico population for paediatric simulations: Application to HIV‐positive African children

British journal of clinical pharmacology, 2021-07, Vol.87 (7), p.2847-2854

2021

Volltextzugriff (PDF)

Understanding the drug exposure–response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug‐resistant tuberculosis

British journal of clinical pharmacology, 2020-05, Vol.86 (5), p.913-922

2020

Volltextzugriff (PDF)

Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations

The Journal of infectious diseases, 2018-08, Vol.218 (6), p.991-999

2018

Volltextzugriff (PDF)

Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB

Journal of antimicrobial chemotherapy, 2017-12, Vol.72 (12), p.3398-3405

2017

Volltextzugriff (PDF)

Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs

Clinical pharmacokinetics, 2021-06, Vol.60 (6), p.685-710

2021

Volltextzugriff (PDF)

High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial

Clinical infectious diseases, 2021-09, Vol.73 (5), p.876-884

2021

Volltextzugriff (PDF)

Clofazimine pharmacokinetics in patients with TB: dosing implications

Journal of antimicrobial chemotherapy, 2020-11, Vol.75 (11), p.3269-3277

2020

Volltextzugriff (PDF)

Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling

Clinical pharmacokinetics, 2022-11, Vol.61 (11), p.1585-1593

2022

Volltextzugriff (PDF)

Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study

Clinical infectious diseases, 2022-08, Vol.75 (1), p.141-151

2022

Volltextzugriff (PDF)

Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development

Frontiers in pharmacology, 2023, Vol.14, p.1067295-1067295

2023

Volltextzugriff (PDF)

Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug

Journal of antimicrobial chemotherapy, 2015-04, Vol.70 (4), p.1106-1114

2015

Volltextzugriff (PDF)

Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis

Clinical pharmacokinetics, 2019-09, Vol.58 (9), p.1103-1129

2019

Volltextzugriff (PDF)

Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin

Clinical pharmacokinetics, 2019-06, Vol.58 (6), p.815-826

2019

Volltextzugriff (PDF)

A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TB

Journal of antimicrobial chemotherapy, 2024-08

2024

Volltextzugriff (PDF)

Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?

Journal of antimicrobial chemotherapy, 2020-03, Vol.75 (3), p.609-617

2020

Volltextzugriff (PDF)

Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy

Clinical pharmacokinetics, 2018-05, Vol.57 (5), p.591-599

2018

Volltextzugriff (PDF)

Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial

Journal of antimicrobial chemotherapy, 2021-11, Vol.76 (12), p.3237-3246

2021

Volltextzugriff (PDF)

Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens

Clinical pharmacology and therapeutics, 2022-10, Vol.112 (4), p.873-881

2022

Volltextzugriff (PDF)

Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa

The Journal of infectious diseases, 2022-08, Vol.226 (1), p.147-156

2022

Volltextzugriff (PDF)

Exposure–safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis

CPT: pharmacometrics and systems pharmacology, 2021-12, Vol.10 (12), p.1538-1549

2021

Volltextzugriff (PDF)

The pharmacokinetics of para‐aminosalicylic acid and its relationship to efficacy and intolerance

British journal of clinical pharmacology, 2020-11, Vol.86 (11), p.2123-2132

2020

Volltextzugriff (PDF)

Optimized Loading Dose Strategies for Bedaquiline When Restarting Interrupted Drug-Resistant Tuberculosis Treatment

Antimicrobial agents and chemotherapy, 2022-03, Vol.66 (3), p.e0174921-e0174921

2022

Volltextzugriff (PDF)

Model-Based Meta-analysis of Rifampicin Exposure and Mortality in Indonesian Tuberculous Meningitis Trials

Clinical infectious diseases, 2020-11, Vol.71 (8), p.1817-1823

2020

Volltextzugriff (PDF)

1 – 25 von 255

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(241)
Mit Volltextzugriff
(235)

Publikationsform

Sprache

Englisch
(254)
Japanisch
(12)
Norwegisch
(3)
Schwedisch
(2)
Dänisch
(1)
Norwegian Nynorsk; Nynorsk, Norwegian
(1)

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis

Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis

Constructing a representative in‐silico population for paediatric simulations: Application to HIV‐positive African children

Understanding the drug exposure–response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug‐resistant tuberculosis

Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations

Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB

Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs

High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial

Clofazimine pharmacokinetics in patients with TB: dosing implications

Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling

Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study

Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development

Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug

Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis

Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin

A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TB

Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?

Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy

Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial

Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens

Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa

Exposure–safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis

The pharmacokinetics of para‐aminosalicylic acid and its relationship to efficacy and intolerance

Optimized Loading Dose Strategies for Bedaquiline When Restarting Interrupted Drug-Resistant Tuberculosis Treatment

Model-Based Meta-analysis of Rifampicin Exposure and Mortality in Indonesian Tuberculous Meningitis Trials

Suchergebnisse filtern